UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~April~~September 166, 2018

Entia Biosciences, Inc.

(Exact name of registrant as specified in charter)

Commission File Number: 000-52864

Nevada

26-0561199

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer Identification No.)

13565 SW Tualatin-Sherwood Road, Suite 800

Sherwood, Oregon

97140

(Address of principal executive offices)

(Zip Code)

(971) 228-0709

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On ~~April~~September 166, 2018, we ~~were~~paid ~~notified~~$38,368 ~~that~~against a judgment that had been entered against Entia Biosciences, Inc. (“Entia”), pursuant to a previously disclosed lawsuit filed against us by “Elite Business Development Services LLC,” (“Elite”), an Oregon limited liability company. Elite was formed by and apparently owned by a former Entia employee, Devin Andres. ~~For~~ ~~the~~The ~~sum of~~ $~~1.00~~38,368 ~~Elite~~paid ~~had~~against ~~arranged~~this tojudgment ~~become~~was anto ~~assignee~~cover ofattorney afees ~~$50,000~~incurred ~~note held~~ by ~~Mark~~Elite ~~Wolf. Although~~and wevarious ~~disputed~~costs ~~the~~related ~~ownership of the note due~~ to ~~a prior agreement between Entia and Wolf,~~ the ~~court~~judgment. ~~ruled~~We inexpect ~~favor~~that ~~of Elite, and entered~~ a ~~judgment~~Satisfaction ~~in the amount~~ of ~~$86,349~~Judgment ~~plus~~for ~~interest. That~~payment ~~judgment was paid~~ in full ~~by us on April 19, 2018 and we anticipate that a Satisfaction of Judgment~~ will be entered in due course.

~~This~~As ~~Current~~previously ~~Report~~disclosed, onfor ~~Form~~the ~~8-K~~sum ~~contains~~of ~~forward-looking~~$1.00, ~~statements~~Elite ~~made~~had ~~pursuant~~arranged to ~~the~~become ~~safe~~an ~~harbor~~assignee ~~provisions~~ of ~~the~~a ~~Private~~$50,000 ~~Securities~~note ~~Litigation~~held ~~Reform~~by ~~Act~~Mark ofWolf. ~~1995,~~Although ~~such~~we asdisputed the ~~timing~~ownership of ~~payments under~~ the ~~Settlement~~note ~~Agreement.~~due ~~Forward-looking information is based on management’s estimates, assumptions and projections, and is subject~~ to ~~significant~~a ~~uncertainties~~prior ~~and~~agreement ~~other~~between ~~factors, many of which are beyond~~ Entia’s ~~control. Important risk factors could cause actual future results~~ and ~~other future events to differ materially from those currently estimated by management. Except as required by applicable law~~Wolf, the ~~Company~~court ~~undertakes~~ruled noin ~~obligation~~favor ~~to publicly update or revise any forward-looking statements, whether as a result~~ of ~~new information~~Elite, ~~future events or otherwise. The Company cannot guarantee the accuracy of the forward-looking statements,~~ and ~~you~~initially ~~should~~entered bea ~~aware~~judgment ~~that~~in the ~~Company’s~~amount ~~actual results could differ materially from those contained in forward-looking statements due to a number~~ of ~~factors~~$86,349 ~~including~~plus ~~the~~interest. ~~statements~~That ~~under~~judgment ~~“Risk~~was ~~Factors”~~paid ~~found~~ in ~~the~~full ~~Company’s~~by ~~Annual~~us ~~Reports~~ on ~~Form~~April ~~10-K~~19, 2018 and ~~its~~a ~~Quarterly~~Satisfaction ~~Reports~~of onJudgment ~~Form~~was ~~10-Q~~duly ~~on file with the Securities and Exchange Commission~~entered.

~~SIGNATURES~~This Current Report on Form 8-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, such as the timing of payments under the Settlement Agreement. Forward-looking information is based on management's estimates, assumptions and projections, and is subject to significant uncertainties and other factors, many of which are beyond Entia’s control. Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The Company cannot guarantee the accuracy of the forward-looking statements, and you should be aware that the Company’s actual results could differ materially from those contained in forward-looking statements due to a number of factors, including the statements under “Risk Factors” found in the Company’s Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q on file with the Securities and Exchange Commission.

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURES

	ENTIA BIOSCIENCES, INC.
	(Registrant)
Date: April 20, 2018	By:	/s/ Timothy A. Timmins
		Timothy A. Timmins
		President and CEO

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENTIA BIOSCIENCES, INC.
	(Registrant)

Date: September 7, 2018	By:	/s/ Timothy A. Timmins
		Timothy A. Timmins
		President and CEO

Filing Compare · Entia Biosciences, Inc.